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Methods Serum samples were collected from 671 patients 
with human epidermal growth factor receptor 2-positive 
locally advanced or metastatic breast cancer (MBC) who 
received single-agent t-DM1 in five phase I to phase III 
studies. nonlinear mixed-effects modeling with the first-
order conditional estimation method was used.
Results a linear two-compartment model with first-
order elimination from the central compartment described 
t-DM1 PKs in the clinical dose range. t-DM1 elimina-
tion clearance was 0.676 l/day, volume of distribution in 
the central compartment (Vc) was 3.127 l, and terminal 
elimination half-life was 3.94 days. age, race, region, and 
renal function did not influence t-DM1 PK. given the low-
to-moderate effect of all statistically significant covariates 
on t-DM1 exposure, none of these covariates is expected 
to result in a clinically meaningful change in t-DM1 
exposure.
Conclusions t-DM1 PK properties are consistent and 
predictable in patients. a further refinement of dose based 
on baseline covariates other than body weight for the cur-
rent 3.6 mg/kg regimen would not yield clinically meaning-
ful reductions in interindividual PK variability in patients 
with MBC.
Keywords ado-trastuzumab emtansine · t-DM1 · 
Her2 · Pharmacokinetics · Metastatic breast cancer
Introduction
trastuzumab emtansine (t-DM1) is an antibody–drug 
conjugate (aDC) comprising the humanized monoclonal 
antibody (mab) trastuzumab conjugated to the highly 
potent cytotoxic agent DM1. t-DM1 delivers DM1 spe-
cifically to human epidermal growth factor receptor 2 
Abstract 
Purpose trastuzumab emtansine (t-DM1) is an anti-
body–drug conjugate comprising the humanized monoclo-
nal antibody trastuzumab linked to DM1, a highly potent 
cytotoxic agent. a population pharmacokinetic (PK) analy-
sis was performed to estimate typical values and interindi-
vidual variability of t-DM1 PK parameters and the effects 
of clinically relevant covariates.
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(Her2)-overexpressing tumor cells [1, 2]. like tras-
tuzumab, t-DM1 induces antibody-dependent cellular 
cytotoxicity, inhibits cell signaling through the phosphati-
dylinositol-3-kinase/aKt pathway, and inhibits Her2 
shedding [2, 3]. Single-agent t-DM1 demonstrated supe-
rior efficacy in treating Her2-positive metastatic breast 
cancer (MBC) in the first-line and relapsed/refractory set-
tings [4, 5] and was recently approved by the US Food 
and Drug administration for the treatment of Her2-posi-
tive MBC [6].
the pharmacokinetics (PKs) of various analytes 
(t-DM1 conjugate, total trastuzumab, and DM1) after 
t-DM1 dosing were characterized in phase I–III stud-
ies by non-compartmental analysis (nCa) [5, 7]. Phase 
I data suggested that t-DM1 conjugate, the major ana-
lyte correlated with treatment efficacy and safety, exhib-
its faster clearance (Cl) at doses ≤1.2 mg/kg and lin-
ear PKs for doses ≥2.4 mg/kg for the every 3-week 
(q3w) regimen [8]. In phase II and phase III studies with 
3.6 mg/kg q3w, linear PK properties were confirmed, 
and no significant accumulation was observed, consist-
ent with its terminal half-life of approximately 4 days 
[9–12]. For the weekly (qw) regimen, modest accumu-
lation of t-DM1 conjugate was observed after the first 
three doses [13].
By targeting delivery, t-DM1 improves the thera-
peutic window of DM1. However, based on the maxi-
mum tolerated dose (MtD) identified for both q3w and 
qw regimens, t-DM1 has a relatively narrow therapeutic 
window compared with typical mabs [7, 8, 13]. there-
fore, it is important to assess the effects of demographic 
and pathophysiologic covariates on the PKs of t-DM1 
to determine whether dose adjustments are needed. to 
estimate typical PK parameter values and interindividual 
variability (IIV) for t-DM1 conjugate, an interim popu-
lation PK (PopPK) model was developed using PK data 
from 273 patients in one phase I (tDM3569g) and two 
phase II studies (tDM4258g and tDM4374g) [14]. to 
support the labeling statement on the PK properties of 
t-DM1 and dosing recommendation, an updated PopPK 
model including data from an additional 400 patients 
from one phase II tDM4450g trial and one phase III reg-
istrational trial (eMIlIa) is reported here. relative to the 
previous report [14] and to better characterize the effects 
of covariates on t-DM1 PK in patients with breast can-
cer, a more comprehensive spectrum of covariates with a 
wider range of values was evaluated. the updated PopPK 
model was also externally validated by another phase II 
study (tDM4688g). the model reported here will be of 
great value for the current clinical application of t-DM1 
in patients with breast cancer.
Materials and methods
Patients, PK serum sampling, and bioanalysis
after the administration of single-agent t-DM1, PK 
data were collected from patients participating in the 
tDM3569g, tDM4258g, tDM4374g, tDM4450g, 
tDM4370g (eMIlIa), and tDM4688g trials [4, 5, 8–10, 
13, 15] (Supplemental table 1). all study designs were 
approved by independent ethics committees and conducted 
in accordance with the Declaration of Helsinki; all patients 
provided written informed consent [4, 5, 8–10, 13, 15].
t-DM1 serum samples were analyzed by the Bioana-
lytical Sciences Department at genentech, Inc., (South San 
Francisco, Ca) or by PPD (richmond, Va) using a validated 
indirect sandwich enzyme-linked immunosorbent assay 
(genentech, Inc., data on file). the conjugate assay quanti-
fied all conjugated trastuzumab containing ≥1 covalently 
bound DM1 molecule, while excluding unconjugated trastu-
zumab. the minimum quantifiable concentration (MQC) of 
the assay ranged from 0.04 to 0.06 µg/ml [16]. Observations 
below the MQC were omitted from the analysis.
establishment and validation of the PopPK final model
PopPK analysis was performed using nonlinear mixed-
effects modeling with first-order conditional estimation 
with interaction method. Model estimation and evaluation 
were implemented with nOnMeM 7 (version 7.1.2; ICOn 
Development Solutions, ellicott City, MD) with Intel For-
tran Compiler (version 10.1.021; Intel, Santa Clara, Ca), 
PerlSpeaksnOnMeM (version 3.2.12; Uppsala University, 
Uppsala, Sweden), and S-PlUS 6.2 (tIBCO Software Inc., 
Palo alto, Ca).
a base model was first established, with all covariates 
likely to impact t-DM1 conjugate exposure (Supplemental 
table 2) explored for a possible correlation with key t-DM1 
post hoc PK parameters. the clinically relevant covariates 
tested included those related to demographics, renal func-
tion, disease severity, and treatment history. the final model 
was identified by testing covariates using stepwise forward 
addition followed by backward deletion. a change in mini-
mum objective function (MOF) at the P < 0.01 level of sig-
nificance (log-likelihood ratio test) was used for the forward 
addition step, and P < 0.001 was used for the backward 
deletion step to retain the covariates in the final model.
Internal validation was performed, including goodness-
of-fit diagnostics, visual predictive check (VPC) plots [17, 
18], numerical predictive check (nPC) [18], bootstrap [19], 
and shrinkage [20] assessments. Compared with internal 
validation, external validation is more rigorous because the 
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model’s predictability is evaluated against a new dataset 
[21–23]. PK data from the phase II study tDM4688g were 
used for external validation (N = 51) [15]. Predicted t-DM1 
serum concentrations for validation patients were obtained 
using post hoc Bayesian forecasting by fixing the param-
eters in the structural and variance models to the final esti-
mates. Population-predicted serum t-DM1 concentrations 
(PreD) were compared with observed t-DM1 concentra-
tions (DV). Prediction errors (Pe) were calculated as (eq. 1):
Bias (mean prediction error [MPe]) was then calculated 
(eq. 2):
where n denotes the number of observations.
the predicted clearance (ClPOP,i) and central volume 
(VcPOP,i) for each patient (per individual covariate values) were 
obtained and compared with the maximum a posteriori prob-
ability (MaP) Bayesian estimates of clearance (ClBayesian,i) 
and central volume (VcBayesian,i) for each validation patient 
based on the available concentration measurements and final 
PopPK parameter estimates. Prediction errors were calculated 
for each individual patient (Pei) and expressed as a percentage 
of the MaP Bayesian estimate (eq. 3):
the bias of prediction was assessed by MPe (eq. 4):
where N denotes the number of patients.
Based on the final model, the effect of extreme values of 
each statistically significant covariate (5th and 95th percen-
tiles) on t-DM1 PK parameters (Cl and Vc) was evaluated. 
to assess whether t-DM1 PKs differed in various popula-
tions, individual Bayesian post hoc Cl and Vc were nor-
malized by statistically significant covariates in the final 
model and compared among clinically relevant populations 
(e.g., those defined by age, race, region, renal function, dis-
ease severity, and treatment history).
Sensitivity analyses
Sensitivity analyses were performed to examine the influence 
of statistically significant covariates on the expected steady-
state exposure of t-DM1 conjugate, including steady-state 


















area under the concentration versus time curve (aUC), 
maximum concentration (Cmax), and trough concentration 
(Ctrough). the simulated exposure of patients with extreme 
covariate values (5th and 95th percentiles) was compared 
with a typical patient with median covariate values for each 
of the statistically significant covariates in the final model.
Model applications: exposure comparison among various 
populations
to compare the expected t-DM1 conjugate steady-state 
exposure in populations defined by age, race, region, or 
renal function, individual t-DM1 exposures (steady-state 
aUC, Cmax, Ctrough) were simulated using Bayesian post 
hoc PK parameters for each patient for multiple doses of 




the development dataset for the final model included 9,934 
t-DM1 conjugate serum concentration–time data points 
from 671 participants in the tDM3569g, tDM4258g, 
tDM4374g, tDM4450g, and tDM4370g (eMIlIa) tri-
als. Of these patients, 643 (95.8 %) received t-DM1 q3w 
and 28 (4.2 %) received t-DM1 qw. the external validation 
dataset contained 505 concentration–time data points from 
51 participants administered t-DM1 q3w in tDM4688g. 
Baseline demographic and clinical characteristics of 
patients included in the PopPK analysis are shown in Sup-
plemental table 3. In total, 7.27 % of all data points were 
below the MQC and thus excluded from the analysis.
Final PopPK model
a linear two-compartment model with first-order elimina-
tion from the central compartment best described t-DM1 
conjugate serum concentration–time data (Supplemental 
Fig. 1). the final PopPK model parameter–covariate rela-
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where Cli, individual patient elimination clearance; ηCl, 
IIV of Cl; ηVc, IIV of Vc; θ1, typical value of Cl; θ2, typical 
value of Vc; θ5, influence of body weight on Vc; θ6, influ-
ence of body weight on Cl; θ7, influence of baseline serum 
Her2 shed extracellular domain concentration (eCD) on 
Cl; θ8, influence of serum albumin concentration (alBU) 
on Cl; θ9, influence of the baseline sum of the longest 
dimension of target lesions (tMBD) on Cl; θ10, influence 
of baseline trastuzumab concentration (tBl) on Cl; θ11, 
influence of serum aspartate aminotransferase concentra-
tion (aSt) on Cl; Vci, individual patient volume of distri-
bution in the central compartment.
Based on the identified statistically significant covari-
ates on Cl and Vc, patients with higher body weight, eCD, 
tMBD, or aSt, or those with lower alBU or tBl, had 
higher Cl; patients with higher baseline body weight had 
higher Vc. In the PopPK model, the estimated typical Cl 
and Vc for t-DM1 were 0.676 l/day and 3.127 l, respec-
tively (table 1). the typical value for the terminal elimina-
tion half-life was 3.94 days, suggesting that t-DM1 conju-
gate does not accumulate after repeated q3w dosing, and 
steady state is reached during the first cycle. the IIV esti-
mated for t-DM1 Cl and Vc from the base model without 
covariates was 25.6 and 17.5 %, respectively, and was fur-
ther reduced in the final model (after incorporating covari-
ate effects) to 19.1 and 11.7 %, respectively; all covariates 
together explained 44.4 and 55.8 % of the IIV in Cl and Vc 
in the base model, respectively.
goodness-of-fit plots showed good agreement between 
predicted and observed concentrations of t-DM1 (Supple-
mental Fig. 2), with no apparent bias in residual plots over 
time or across population-predicted concentrations (Sup-
plemental Fig. 3). VPC plots (Supplemental Fig. 4a) and 
nPC (data not shown) showed that the final PopPK model 
could adequately reproduce the central tendency and varia-
bility of the t-DM1 conjugate serum concentrations across 
all studies for the labeled regimen, 3.6 mg/kg q3w.
Bootstrapping of 1,000 datasets resulted in median 
parameter estimates and 95 % confidence intervals (CIs) 
similar to the estimates from the original dataset (data not 
shown), indicating that the final PopPK model provided 
good precision for parameter estimation. the ε-shrinkage 
was 6.1 %, and η-shrinkage [20] for Cl was 15.6 %; there-
fore, the Bayesian estimates for Cl were robust enough to 
estimate the relationship between Cl and related covari-
ates. the η-shrinkage for Vc, distribution clearance (Q), 
and volume of distribution in the peripheral compartment 
(Vp) were 38.5, 49.7, and 36.1 %, respectively.
the external validation dataset was well predicted by 
the final model based on goodness-of-fit plots (data not 
shown), VPC (Supplemental Fig. 4B), and nPC (data not 
shown). no bias was observed over time or across PreD. 
Table 1  typical and 95 % CIs for PopPK parameter estimates from the final model
%CV the mean percentage coefficient of variation, ALBU serum albumin concentration, AST serum aspartate aminotransferase concentration, CI 
confidence interval, CL elimination clearance, ECD baseline serum human epidermal growth factor receptor 2 shed extracellular domain concen-
tration, PopPK population pharmacokinetic, Q distribution clearance, TBL baseline trastuzumab concentration, TMBD baseline sum of longest 
dimension of target lesions, Vc volume of distribution in the central compartment, Vp volume of distribution in the peripheral compartment
Parameter Parameter description Final PopPK model point 
estimates (95 % CI)
exp(θ1)*24 Cl (l/day) 0.676 (0.661–0.691)
θ6 Influence of weight on Cl 0.49 (0.41–0.57)
θ7 Influence of eCD on Cl 0.035 (0.021–0.05)
θ8 Influence of alBU on Cl –0.423 (–0.553 to –0.293)
θ9 Influence of tMBD on Cl 0.052 (0.033–0.071)
θ10 Influence of tBl on Cl −0.002 (−0.002 to −0.001)
θ11 Influence of aSt on Cl 0.071 (0.036–0.106)
exp(θ2) Vc (l) 3.127 (3.08–3.174)
θ5 Influence of weight on Vc 0.596 (0.526–0.666)
exp(θ3)*24 Distribution Cl (Q; l/day) 1.534 (1.286–1.83)
exp(θ4) Vp (l) 0.66 (0.58–0.752)




ω2CL,Vc Covariance between Cl and Vc 0.011 (0.008–0.015)
Σ residual variability (% CV) 31.56 (31.07–32.04)
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the final PopPK model accurately predicted t-DM1 conju-
gate concentrations, individual Cl and Vc in the validation 
patients with minimal bias (represented by MPe values) of 
2.70 % (95 % CI −9.87 to 4.48), 1.97 % (95 % CI −7.17 to 
3.23), and −2.20 % (95 % CI −4.25 to –0.15), respectively. 
none significantly differed from zero at the P > 0.01 level 
of significance.
Impact of covariates on PK parameters
the effect of extreme values (5th and 95th percentiles 
for 671 patients) of statistically significant covariates on 
t-DM1 Cl and Vc was assessed. Despite statistical signifi-
cance, the impact of their variation for a single covariate 
on key t-DM1 PK parameters was low: <20 % for Cl and 
<25 % for Vc (table 2).
age, race, and calculated baseline creatinine clearance 
(CrCl) using the Cockcroft-gault formula [24, 25] were 
not statistically significant covariates for PK parameters. 
Patients grouped by age, race, geographic region, and renal 
function (normal vs. mild impairment vs. moderate impair-
ment based on CrCl [25]) had similar covariate-normal-
ized Cl or Vc (Fig. 1). the lower Bayesian post hoc Cl and 
Vc estimates observed for asian patients were likely due to 
the covariate effect of body weight on Cl and Vc, as asian 
patients had a slightly lower body weight versus non-asian 
patients (mean body weight, 60.5 versus. 71.6 kg).
alBU, tMBD, and eCD were disease severity-related 
baseline covariates identified as being statistically sig-
nificant for t-DM1 Cl in the final PopPK model (Fig. 2). 
Patients with lower alBU or higher tMBD or eCD tended 
to have higher Cl; however, the extreme values of a single 
covariate on Cl resulted in a <10 % change from a typical 
patient (table 2). Other covariates related to disease sever-
ity (e.g., disease measurability, visceral disease, and east-
ern Cooperative Oncology group performance status) did 
not affect Cl (Fig. 2) or Vc (data not shown).
among covariates related to treatment history, tBl was 
identified as a statistically significant covariate for t-DM1 
Cl but not for Vc. the extreme values of a single covariate 
on Cl resulted in a <10 % change from a typical patient 
(see table 2). Whether patients received prior systemic 
therapy in the locally advanced or metastatic settings did 
not appear to affect Cl (Fig. 2) or Vc (data not shown).
Sensitivity analyses
Sensitivity analyses (Fig. 3) suggested that the magnitude 
of effect of all statistically significant covariates on t-DM1 
conjugate steady-state aUC (<19 %) and Cmax (<15 %) was 
Table 2  effect of covariates on 
t-DM1 PK parameters
ALBU serum albumin 
concentration, AST serum 
aspartate aminotransferase 
concentration, CL elimination 
clearance, ECD baseline serum 
human epidermal growth factor 
receptor 2 shed extracellular 
domain concentration, PK 
pharmacokinetic, TBL baseline 
trastuzumab concentration, 
T-DM1 trastuzumab emtansine, 
TMBD baseline sum of longest 
dimension of target lesions, Vc 
volume of distribution in the 
central compartment
a
 a 70-kg patient with eCD 
of 25 ng/ml, alBU of 41 g/l, 
tMBD of 9 cm, tBl of 0 µg/
ml, and aSt of 27 U/l




estimate Percent change 
from typical
typical Cl (l/day)a 0.676
Body weight (kg)
 5th percentile 49 0.567 –16.04
 95th percentile 98 0.797 17.92
eCD (ng/ml)
 5th percentile 8.5 0.650 –3.747
 95th percentile 332 0.741 9.588
alBU (g/l)
 5th percentile 33 0.741 9.617
 95th percentile 48 0.632 –6.450
tMBD (cm)
 5th percentile 1.5 0.616 –8.831
 95th percentile 30.3 0.719 6.464
tBl (µg/ml)
 5th percentile 0 0.676 0.000
 95th percentile 54 0.615 –9.017
aSt (IU/l)
 5th percentile 15.3 0.649 –3.936
 95th percentile 64 0.718 6.292
typical Vc (L) for a 70-kg patient 3.127
Body weight (kg)
 5th percentile 49 2.523 –23.69
 95th percentile 98 3.821 18.17
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Fig. 1  Comparison of t-DM1 
PK parametersa for patients by 
a age, b race, c region, and d 
renal functionb. anormalized 
for body weight of 70 kg, eCD 
of 25 ng/ml, alBU of 41 g/l, 
tMBD of 9 cm, tBl of 0 μg/
ml, and aSt of 27 U/l. bnor-
mal: CrCl ≥ 90 ml/min; mild: 
CrCl = 60–89 ml/min; moder-
ate: CrCl = 30–59 ml/min; 
severe: CrCl = 15–29 ml/min. 
Circles indicate individual Cl 
or Vc estimates. the red lines 
indicate typical population-pre-
dicted covariate relationships, 
and the blue squares are the 
means of individual estimates. 
ALBU serum albumin concen-
tration, AST serum aspartate 
aminotransferase concentration, 
CL elimination clearance, CrCL 
baseline creatinine clearance, 
ECD baseline serum human epi-
dermal growth factor receptor 2 
shed extracellular domain con-
centration, PK pharmacokinetic, 
TBL baseline trastuzumab con-
centration, T-DM1 trastuzumab 
emtansine, TMBD baseline sum 
of the longest dimension of the 
target lesion, US United States, 
Vc volume of distribution in 
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low and moderate on t-DM1 conjugate Ctrough (<41 %). Of 
note, Ctrough is associated with greater variability than aUC 
and Cmax. Baseline body weight was the covariate with the 
greatest effect on t-DM1 steady-state aUC and Cmax (see 
Fig. 3). given the low IIV of t-DM1 key PK parameters 
(Cl and Vc) and the low-to-moderate effect of all statisti-
cally significant covariates on t-DM1 exposure (Cmax, 
Ctrough, aUC), no covariate is expected to have clinically 
meaningful effects on t-DM1 exposure.
Model applications: exposure comparison among various 
populations
all exposure parameters were similar across age groups 
(<65, 65–75, >75 years) (Supplemental table 4). thus, 
dose adjustment in elderly patients is not justified.
asian patients and patients enrolled in asia had a <7 % 
lower mean aUC with largely overlapping intervals of the 
5th to 95th percentile (Supplemental table 4). However, 
this difference is likely due to body weight rather than to 
race or region. asian patients had an approximately 16 % 
lower body weight (60.5 kg) versus non-asian patients 
(71.6 kg) and received a lower amount of t-DM1 under 
body weight-based dosing. thus, no dose adjustment based 
on race or region is considered necessary.
Patients with mild or moderate renal impairment had 
a <11 % lower mean aUC value with largely overlap-
ping intervals of the 5th to 95th percentile (Supplemental 
table 4). CrCl, as calculated by the Cockcroft-gault for-
mula [24, 25], is correlated with body weight. Due to their 
lower body weight, patients with mild or moderate renal 
impairment received lower amounts of t-DM1 under body 
weight-based dosing versus patients with normal renal 
function. as exposure differences are not caused directly by 
renal function, dose adjustment based on renal function is 
not necessary. However, because of the limited numbers of 
patients, no conclusions can be drawn regarding the effects 
of severe renal impairment (n = 1) or end-stage renal dis-
ease (n = 0) on t-DM1 exposure.
Discussion
results from this PopPK analysis informed the prescrib-
ing information for t-DM1 in patients with Her2-positive 
MBC, specifically its PK properties and dose justification 
based on the impact of weight, age, race, region, renal 
function, treatment history, and disease and health status on 
PKs. the model can reliably predict t-DM1 exposure and 
IIV irrespective of prior trastuzumab treatment.
linear PKs were observed in patients receiving clini-
cally relevant t-DM1 doses (2.4–4.8 mg/kg q3w). t-DM1 
Cl appeared to be faster in the five patients who received 
t-DM1 doses of ≤1.2 mg/kg q3w, likely due to target-
mediated disposition at low doses. However, the PopPK 
model parameters associated with nonlinear elimination 
were not estimated with good precision, possibly because 
of the limited amount of data available for these lower 
doses of t-DM1. Sensitivity analyses indicated that the 
inclusion/exclusion of PK data from these five patients did 
not impact PK parameter estimation.
the t-DM1 Cl (0.676 l/day) is approximately three 
times faster than that of unconjugated trastuzumab (approx-
imately 0.2 l/day) [26]. the elimination half-life of t-DM1 
(approximately 4 days) is shorter than that for a typical 
immunoglobulin g1 antibody (2–3 weeks) [27]. these 
data support multiple mechanisms of t-DM1 Cl. t-DM1 
undergoes both target-mediated (Her2) and non-specific 
(partly Fc-mediated) proteolytic degradation, similar to that 
of mabs [28]. Moreover, DM1 deconjugation from t-DM1 
may contribute to t-DM1 Cl, which may partially explain 
the faster Cl and shorter half-life of t-DM1 [29]. the cen-
tral volume of distribution of t-DM1 for a 70-kg patient 
is 3.127 l, which is similar to that of unconjugated tras-
tuzumab (~2.95 l) ([26]), other mabs (~2.4–5.5 l) ([27]), 
and aDCs such as brentuximab vedotin (4.16 l) [30]. the 
peripheral volume of distribution of t-DM1 is relatively 
small (0.66 l) and is lower than that of brentuximab vedo-
tin (8.06 l) [30]. Overall, the PK properties of t-DM1 are 
more similar to a mab than to a small molecule drug, with 
relatively slow Cl and a small volume of distribution that 
is mostly confined to plasma.
the linker used in aDCs may affect Cl by impacting 
the rate of deconjugation of the cytotoxic drug component. 
Several linkers have been used in various compounds in 
clinical development. For example, t-DM1 contains a non-
cleavable thioether linker (4-(N-malemidomethyl) cyclohex-
ane-1-carboxylate [MCC]); brentuximab vedotin contains 
a peptide-based linker (maleimidocaproyl-valine-citruline-
p-aminobenzyl-oxycarbonyl [MC-vc-PaB]); inotuzumab 
ozogamicin and gemtuzumab ozogamicin contain acid-
labile linkers (4-(4-acetylphenoxy)butanoic acid [acBut]); 
and aVe9633 and SVr3419 contain disulfide linkers 
(N-succinimidyl-3-(2′-pyridyldithio) butyrate [SPDB]). 
t-DM1, with its MCC linker, has a Cl rate (~0.7 l/day) 
similar to aDCs containing SPDB linkers (aVe9633 200–
260 mg/m2, ~0.9–1.1 l/day [31, 32]; Sar3419, ~0.6 l/day 
[33]). However, higher Cl values have been observed for 
aDCs containing MC-vc-PaB linkers (brentuximab vedo-
tin 1.8 mg/kg, ~1.5–1.8 l/day [30, 32, 34]) or acBut linkers 
(inotuzumab ozogamicin 1.8 mg/m2, ~2.2–3.8 l/day [32, 35, 
36]; gemtuzumab ozogamicin 0.23 mg/kg, ~3.2 l/day [32, 
37]). the lower Cl of t-DM1 at clinically relevant doses 
(i.e., when target-mediated Cl is largely saturated) might be 
attributable to its non-cleavable linker, which results in less 
rapid deconjugation of the cytotoxic component.
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the relatively small IIV of t-DM1 Cl and Vc (~19 and 
12 %, respectively, table 1) is consistent with the expected 
IIV of mabs (~30–40 %) [27]. the IIV estimated for Q 
and Vp was relatively high in the final PopPK model, likely 
because of the limited data in the terminal phase of the phase 
II and phase III trials. a relatively large η-shrinkage of >30 % 
for Vc, Q, and Vp was observed in the final model, suggest-
ing that PK data may not sufficiently characterize the IIV for 
these parameters. More intensive concentration–time data 
may improve the accuracy of the IIV estimation, especially 
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for Q and Vp, which had relatively high η-shrinkage in both 
the base (data not shown) and final models.
the body weight-based regimen of 3.6 mg/kg was estab-
lished as the MtD for t-DM1 in phase I testing [8]. Per a 
theoretical simulation comparing flat versus body weight-
based dosing [38], flat dosing would not be expected to 
reduce IIV, given that body weight impacts t-DM1 Cl and 
Vc with exponential function values of 0.5 and 0.6, respec-
tively (table 1, parameters θ6 and θ5). Sensitivity analyses 
suggested that the magnitude of the impact of body weight 
on t-DM1 PK parameters (Cl, Vc) and exposure (aUC, 
Cmax, Ctrough) is relatively small (<25 %) (table 2; Fig. 3).
t-DM1 conjugate was cleared more slowly in patients 
with lower body weight (table 2); however, conjugate 
exposure was lower in lighter patients due to body weight-
based dosing (Fig. 3). Of the 671 patients included in this 
analysis, 68 (10.1 %) weighed ≥90 kg and thus received 
a greater amount of t-DM1 versus the overall population. 
these patients had higher mean exposure (21.0 % higher 
for aUC, 18.4 % higher for Cmax, 19.1 % higher for Ctrough, 
with largely overlapping intervals of 5th to 95th percen-
tiles), despite faster Cl and larger Vc. Furthermore, based 
on the exposure–response analysis of t-DM1 3.6 mg/kg 
q3w [7, 12, 39, 40], the variability in t-DM1 aUC and 
Cmax is not expected to have a clinically meaningful impact 
on overall safety; thus, the current body weight-based regi-
men remains appropriate, with no further dose adjustment 
recommended for heavier patients.
the covariates of age, race, and geographic region were 
not significant, suggesting that no further dose adjustment 
based on these covariates is necessary. although asian 
patients and patients from asia have lower mean exposures, 
these differences are likely due to lower body weight. 
Based on the exposure–response analysis of t-DM1 
3.6 mg/kg q3w [7, 12, 39, 40], this exposure variability 
is not expected to have a clinically meaningful impact on 
safety.
Compared with the earlier PopPK model that included 
only phase I and phase II data [14], two additional covari-
ates (eCD and tBl) were identified as significantly 
impacting t-DM1 Cl in the revised updated PopPK model. 
this may be a consequence of the increased number of 
patients in the second- and third-line treatment settings, 
patients who introduced a larger dynamic range for these 
two covariates. However, the effects of eCD and tBl 
were not considered clinically meaningful because of the 
small-to-moderate magnitude of effect on aUC, Cmax, and 
Ctrough. Mechanistically, eCD and tMBD are highly cor-
related with total Her2 antigen concentration, and their 
correlation with t-DM1 Cl suggests a potential mecha-
nism of Her2 target-mediated Cl of t-DM1. these find-
ings are similar to those from a PopPK analysis of tras-
tuzumab, where eCD was also found to be a statistically 
significant covariate for trastuzumab Cl [26]. While high 
baseline tBl resulting from prior trastuzumab treatment 
may increase total trastuzumab exposure and compete with 
t-DM1 for the Her2-mediated Cl pathway, the effects of 
this covariate on exposure do not appear to translate into 
clinically relevant differences in safety [12, 39, 40].
although tMBD (and potentially overall disease sever-
ity) for most patients decreased over time and after repeated 
t-DM1 infusions (because of shrinkage of target lesions 
following treatment), t-DM1 PKs do not appear to change 
over time. Model diagnostic plots did not suggest the exist-
ence of apparent bias of residual versus time (Supplemen-
tal Fig. 3), further indicating that inclusion of time-varying 
covariates for this patient population may not be necessary. 
Based on nCa, similar PK parameters were observed in 
cycle 1 and after several doses of t-DM1 (data not shown), 
suggesting that the PKs of t-DM1 are not largely affected 
by tumor size or changes in disease severity after treatment; 
this may be due to the relatively small magnitude of effect 
of tMBD on t-DM1 Cl and exposure.
given the high molecular weight of t-DM1, renal func-
tion is unlikely to impact Cl. Based on preclinical studies, 
t-DM1 is mainly eliminated through bile after conversion 
to DM1-containing catabolites, with minimal (<5 %) renal 
elimination [41]. t-DM1 PK parameters (Cl, Vc) after nor-
malization of other covariates were similar in patients with 
varying degrees of renal function (normal, mild impair-
ment, or moderate impairment [per calculated CrCl]). 
thus, renal impairment is not expected to impact t-DM1 
PKs.
Fig. 2  t-DM1 PK parameter–covariate relationships for baseline 
disease severity and prior treatment history, a alBU, b tMBD, 
c eCD, d tBl, e DMe, f eCOg, g VISC, h PSt. anormalized for 
body weight of 70 kg, tBl of 0 μg/ml, eCD of 25 ng/ml, aSt of 
27 U/l, and tMBD of 9 cm. bnormalized for body weight of 70 kg, 
alBU of 41 g/l, tBl of 0 μg/ml, eCD of 25 ng/ml, and aSt of 
27 U/l. cnormalized for body weight of 70 kg, alBU of 41 g/l, 
tBl of 0 μg/ml, aSt of 27 U/l, and tMBD of 9 cm. dnormal-
ized for body weight of 70 kg, alBU of 41 g/l, eCD of 25 ng/ml, 
aSt of 27 U/l, and tMBD of 9 cm. enormalized for body weight of 
70 kg, alBU of 41 g/l, tBl of 0 μg/ml, eCD of 25 ng/ml, aSt 
of 27 U/l, and tMBD of 9 cm. Points indicate individual parameter 
estimates. In a–b blue lines indicate a typical (population) predicted 
covariate relationship. the red boxes represent a statistically sig-
nificant PK parameter–covariate relationship. In e–g red lines indi-
cate a typical (population) predicted covariate relationship. the blue 
squares represent the means of individual estimates. ALBU serum 
albumin concentration, AST serum aspartate aminotransferase con-
centration, CL elimination clearance, DME disease measurability, 
ECD baseline serum human epidermal growth factor receptor 2 shed 
extracellular domain concentration, ECOG baseline eastern Coopera-
tive Oncology group performance status score, PK pharmacokinetic, 
PST prior systemic therapy in the locally advanced/metastatic setting, 
TBL trastuzumab baseline concentration, T-DM1 trastuzumab emtan-
sine, TMBD baseline sum of the longest dimension of target lesions, 
VISC visceral disease
◂
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Some covariates related to hepatic function were 
tested in this analysis, with alBU and aSt identified as 
being statistically significant. a dedicated phase I study 
(BO25499) of t-DM1 in patients with MBC and normal 
or mild/moderate hepatic impairment is ongoing; PKs and 
safety results will be reported separately. PKs in patients 
with early-stage breast cancer characterized by lower base-
line tumor burden and non-metastatic disease status are 
also being evaluated.
Conclusion
the t-DM1 PK properties are consistent and predictable in 
patients with Her2-positive MBC. age, race, region, and 
renal function did not influence t-DM1 PKs. given the low 
IIV of t-DM1 key PK parameters (Cl and Vc) and the low-
to-moderate effect of statistically significant covariates on 
t-DM1 exposure, a further refinement of dose based on base-
line covariates other than body weight for the current 3.6 mg/
kg regimen would not yield clinically meaningful reductions 
in interindividual PK variability in this patient population.
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